Law360
The Way Forward For COVID-19 Testing In The U.S.
May 11, 2020
The public debate over severe acute respiratory syndrome coronavirus 2, the pathogen responsible for COVID-19, has become dominated by questions about diagnostic testing. On April 24, President Donald Trump signed bipartisan legislation funding a national COVID-19 testing program with significant state and local responsibility for scale up, contact tracing and employer testing.
Despite $25 billion allocated to COVID-19 testing, major challenges will confront authorities as they seek to make accurate testing available across the country. On April 27, the White House unveiled its blueprint for coronavirus testing through a partnership involving federal, state, local and tribal governments, and the private sector.
Contacts
Related Resources
Capabilities
Suggested News & Insights
Digital Health Transformation: A Practical Guide for Life Sciences CompaniesJanuary 18, 20232023 — The Year “Modernization” Comes to the U.S. Cosmetics IndustryJanuary 5, 2023U.S. Oversight Agencies Identify Program Integrity Risks Related to Increased Telehealth Usage During the PandemicDecember 13, 2022Switzerland Will Open Its Market for U.S. Food & Drug Administration (FDA) - Regulated Medical DevicesDecember 7, 2022One Step Forward, Two Steps Back: FDA’s Final Guidance on Clinical Decision Software Raises More Questions Than AnswersOctober 26, 2022New Swiss Data Protection Act – And a New Swiss-U.S. Trans-Atlantic Data Privacy Framework?October 25, 2022
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


